Xenon Pharmaceuticals (XENE) Shares Outstanding (Diluted Average) (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 13 years of Shares Outstanding (Diluted Average) data on file, last reported at $87.3 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $87.3 million, up 11.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $87.3 million (up 11.0% YoY), and the FY2024 annual result was $77.9 million, up 16.45% from the prior year.
• Shares Outstanding (Diluted Average) climbed to $87.3 million in Q1 2026 per XENE's latest filing, from $79.0 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $87.3 million in Q1 2026 and troughed at $54.9 million in Q1 2022.
• A 5-year average of $71.0 million and a median of $72.2 million in 2023 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Diluted Average) jumped 62.06% in 2022, then rose 0.82% in 2023.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $60.5 million in 2022, then climbed by 10.48% to $66.9 million in 2023, then increased by 16.45% to $77.9 million in 2024, then grew by 1.37% to $79.0 million in 2025, then advanced by 10.62% to $87.3 million in 2026.
• Business Quant data shows XENE's Shares Outstanding (Diluted Average) at $87.3 million in Q1 2026, $79.0 million in Q3 2025, and $79.0 million in Q2 2025.